Venture Life Group (LON:VLG), which develops consumer healthcare products, reported annual revenues of £35.1 million for the year ended December 31, 2025, representing a 32% rise compared with the prior year.
Adjusted to a proforma basis - treating acquisitions as if they had been held for the entirety of the previous year - the company said revenues increased by 11.1% year-on-year. The proforma gain comprised a 0.9% contribution from price increases and a 10.2% uplift attributable to higher volumes sold.
The company's Power Brands segment - made up of Balance Activ, Lift/Glucogel, Earol, and Health & Her/Him - expanded by 14.9% to reach £33.1 million for the year.
Geographically, the UK market delivered particularly strong results. UK revenues rose 20.7% to £25.7 million, a performance the company linked to stepped-up advertising and promotional investment.
- Balance Activ posted the largest brand-level gain, with revenues up 37% to £4.3 million.
- Earol sales increased 11.5% to £3.2 million.
- The Lift brand recovered in the second half and finished the year up 4.9% at £7.3 million.
- Brands acquired in November 2024 under the Health & Her/Him banner delivered 44% proforma growth, reaching £8.5 million.
By contrast, the company reported an 8.7% decline in its international business, which fell to £9.4 million. Venture Life attributed that drop to the timing of partner orders and temporary distributor disruptions in Scandinavia.
Strategic changes in 2025 included the disposal of the company's CDMO operations, a move that repositioned Venture Life as a pure branded consumer healthcare business. As part of a reorganisation of its international footprint, the company closed its Spanish office and transferred those functions into the UK-based commercial team.
On the balance sheet, Venture Life held net cash of £34.4 million as at December 31, 2025. The company also resumed shareholder returns via a share buyback programme announced in September 2025; to date that programme has returned £1.1 million to shareholders through the purchase of approximately 1.7 million ordinary shares.
Chief Executive Officer Jerry Randall commented on the results, saying the higher advertising and promotional spend in the UK had been "vindicated by the revenue growth seen across the Power Brands which are well ahead of sector norms." He added that the group entered 2026 with "great momentum" and said it was "very active in pursuing the right M&A opportunities."
The results underscore a transitionary year for Venture Life: a shift away from contract manufacturing towards a concentrated branded consumer healthcare model, supported by targeted marketing investment in its core UK market and continued balance-sheet flexibility.